We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RedHill Gets Two New Patents for Crohn's Disease Candidate
Read MoreHide Full Article
Shares of RedHill Biopharma Ltd (RDHL - Free Report) have risen almost 12% after it announced allowance of two new patents for its key late-stage pipeline candidate, RHB-104.
In fact, so far this year, RedHill Biopharma stock has soared 85.3%, significantly outperforming the industry’s increase of 3%.
RedHill Biopharma announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance while the European Patent Office gave an Intention to Grant two new patents to the company’s pipeline candidate, RHB-104.
If granted, the patent is likely to be valid till Feb 5, 2029. RHB-104 has a robust patent portfolio consisting of 30 patents including five in the United States.
RHB-104 is being evaluated in a phase III study for the treatment of moderate to severe active Crohn’s disease caused by mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients (the MAP US study). Top-line results from the study are expected in the coming weeks.
Earlier in May, the company announced that the last patient enrolled in the trial completed 26 weeks of treatment for primary endpoint evaluation.
Separately, an open-label extension phase III study (MAP US2 study) is ongoing to evaluate the safety and efficacy of RHB-104 on patients, who remain with active Crohn’s disease after 26 weeks of blinded study therapy in the ongoing Phase III MAP US study. RedHill Biopharma plans to submit a new drug application (NDA) for RHB-104 provided the MAP US study outcomes are positive with additional trials likely to be required in support of the NDA filing.
RedHill Biopharma currently carries a Zacks Rank #2 (Buy). Other stocks worth considering from the pharma sector include ChemoCentryx, Inc. , CRISPR Therapeutics (CRSP - Free Report) and Taro Pharmaceutical Industries Ltd. (TARO - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here
ChemoCentryx’s loss per share estimates has been narrowed by 24% for 2018 and 0.8% for 2019 in the last 60 days. The stock has skyrocketed 113.3% year to date.
CRISPR Therapeutics’ loss per share estimates has been narrowed by 7.8% for 2018 and 9% for 2019 in the last 60 days. The stock has soared by a staggering 160.9% year to date.
Taro Pharmaceutical’s earnings estimates have been revised 13% upward for 2018 and 12.4% for 2019 in the past 60 days. The stock has gained 9.8 % so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
RedHill Gets Two New Patents for Crohn's Disease Candidate
Shares of RedHill Biopharma Ltd (RDHL - Free Report) have risen almost 12% after it announced allowance of two new patents for its key late-stage pipeline candidate, RHB-104.
In fact, so far this year, RedHill Biopharma stock has soared 85.3%, significantly outperforming the industry’s increase of 3%.
RedHill Biopharma announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance while the European Patent Office gave an Intention to Grant two new patents to the company’s pipeline candidate, RHB-104.
If granted, the patent is likely to be valid till Feb 5, 2029. RHB-104 has a robust patent portfolio consisting of 30 patents including five in the United States.
RHB-104 is being evaluated in a phase III study for the treatment of moderate to severe active Crohn’s disease caused by mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients (the MAP US study). Top-line results from the study are expected in the coming weeks.
Earlier in May, the company announced that the last patient enrolled in the trial completed 26 weeks of treatment for primary endpoint evaluation.
Separately, an open-label extension phase III study (MAP US2 study) is ongoing to evaluate the safety and efficacy of RHB-104 on patients, who remain with active Crohn’s disease after 26 weeks of blinded study therapy in the ongoing Phase III MAP US study. RedHill Biopharma plans to submit a new drug application (NDA) for RHB-104 provided the MAP US study outcomes are positive with additional trials likely to be required in support of the NDA filing.
RedHill Biopharma currently carries a Zacks Rank #2 (Buy). Other stocks worth considering from the pharma sector include ChemoCentryx, Inc. , CRISPR Therapeutics (CRSP - Free Report) and Taro Pharmaceutical Industries Ltd. (TARO - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here
ChemoCentryx’s loss per share estimates has been narrowed by 24% for 2018 and 0.8% for 2019 in the last 60 days. The stock has skyrocketed 113.3% year to date.
CRISPR Therapeutics’ loss per share estimates has been narrowed by 7.8% for 2018 and 9% for 2019 in the last 60 days. The stock has soared by a staggering 160.9% year to date.
Taro Pharmaceutical’s earnings estimates have been revised 13% upward for 2018 and 12.4% for 2019 in the past 60 days. The stock has gained 9.8 % so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>